Molecular Partners AG (ticker: MOLN) is a Swiss biopharmaceutical company pioneering the development of a new class of custom-built protein therapeutics. The primary thrust of their work revolves around developing DARPin® therapeutics, a class of protein therapeutics that opens avenues for new therapies to treat diseases with unmet medical needs. DARPin® therapeutics have the ability to engage multiple targets, offering potential benefits over conventional single-targeted antibody approaches.
The company has been operating since 2004 and is headquartered in Zurich. Molecular Partners AG is listed on the SIX Swiss Exchange under the ticker MOLN. As of 2021, its workforce totals around 130 employees.
The company's clinical pipeline includes several investigational DARPin® candidates, some in collaboration with pharmaceutical giants like Allergan and Amgen. These collaborations reflect the growing industry acceptance of Molecular Partners' novel therapeutics approach. The company focuses on three primary therapeutic areas - oncology, ophthalmology, and infectious diseases.
In Oncology, Molecular Partners AG is exploring the use of the DARPin® platform to create therapies that confront the complexity of cancer, from bi-specifics for individualized tumor-directed immunotherapy to trimers for anti-angiogenic treatments.
In Ophthalmology, Molecular Partners has found significant success, particularly with wet age-related macular degeneration (AMD) treatment. Abicipar, a DARPin® candidate, is developed in partnership with AbbVie in the US and EU. This is a clear indication of the acceptance of Molecular Partners' DARPin® platform by mainstream medicine.
With regard to infectious diseases, Molecular Partners AG is developing DARPin® molecules targeting infectious diseases such as the novel coronavirus. The company's antiviral candidate, ensovibep (MP0420), is currently being investigated as a potential treatment for COVID-19.
Molecular Partners AG continues to embody the innovative spirit of pharmaceutical research, pioneering techniques and treatments that hold promise for the future. Its DARPin® platform represents a revolutionary approach to traditional therapies, and collaborations with major pharmaceutical companies underscore its potential. The company’s comprehensive approach to addressing the challenges of modern medicine positions it at the forefront of the biotechnological industry.